Incyte Stock Today
| INCY Stock | USD 74.40 0.39 0.53% |
PerformanceVery Weak
| Odds Of DistressVery Low
|
Incyte is trading at 74.40 as of the 25th of February 2025; that is 0.53% increase since the beginning of the trading day. The stock's open price was 74.01. Incyte has under 5 % chance of experiencing financial distress over the next 2 years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 27th of November 2024 and ending today, the 25th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 4th of November 1993 | Category Healthcare | Classification Health Care |
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware. The company has 193.52 M outstanding shares of which 5.79 M shares are currently shorted by private and institutional investors with about 4.24 trading days to cover. More on Incyte
Moving against Incyte Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Incyte Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman | Herve Hoppenot | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, SP 500 Index, ARCA Biotechnology, Dow Jones Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Excise Tax Activities | Animal Testing | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsIncyte can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Incyte's financial leverage. It provides some insight into what part of Incyte's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Incyte (INCY) is traded on NASDAQ Exchange in USA. It is located in 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803 and employs 2,617 people. Incyte is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 14.32 B. Incyte conducts business under Biotechnology sector and is part of Health Care industry. The entity has 193.52 M outstanding shares of which 5.79 M shares are currently shorted by private and institutional investors with about 4.24 trading days to cover.
Incyte currently holds about 2.72 B in cash with 335.34 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.24.
Check Incyte Probability Of Bankruptcy
Ownership AllocationIncyte has a total of 193.52 Million outstanding shares. The majority of Incyte outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Incyte to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Incyte. Please pay attention to any change in the institutional holdings of Incyte as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Incyte Ownership Details
Incyte Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Bellevue Group Ag | 2024-12-31 | 2.2 M | |
| Armistice Capital, Llc | 2024-12-31 | 1.8 M | |
| Norges Bank | 2024-12-31 | 1.8 M | |
| Northern Trust Corp | 2024-12-31 | 1.7 M | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 1.6 M | |
| Ubs Asset Mgmt Americas Inc | 2024-12-31 | 1.5 M | |
| Dimensional Fund Advisors, Inc. | 2024-12-31 | 1.3 M | |
| Point72 Asset Management, L.p. | 2024-12-31 | 1.3 M | |
| Robeco Institutional Asset Management Bv | 2024-12-31 | 1.3 M | |
| Baker Bros Advisors Lp | 2024-12-31 | 30.7 M | |
| Vanguard Group Inc | 2024-12-31 | 19.6 M |
Incyte Historical Income Statement
Incyte Stock Against Markets
Incyte Corporate Management
| Mr MD | Head VP | Profile | |
| Sheila JD | General VP | Profile | |
| Thomas Tray | Chief Finance | Profile | |
| Pamela Murphy | Vice Communications | Profile | |
| Patrick Mayes | Vice Research | Profile | |
| Paula Swain | Executive Resources | Profile | |
| Christine Chiou | Head Relations | Profile |
Additional Tools for Incyte Stock Analysis
When running Incyte's price analysis, check to measure Incyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte is operating at the current time. Most of Incyte's value examination focuses on studying past and present price action to predict the probability of Incyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Incyte's price. Additionally, you may evaluate how the addition of Incyte to your portfolios can decrease your overall portfolio volatility.